#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3158	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2554	366.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1726	1726	C	493	C,T	408,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3158	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2554	366.2	0	HET	.	.	.	A308G	.	308	308	A	850	850	A	412	A,G	274,79	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5174	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3964	390.5	0	.	n	.	0	T695C	SNP	695	695	T	1237	1237	C	368	C,T	303,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5174	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3964	390.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1879	1879	A	433	A,C	382,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5174	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3964	390.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2513	2513	C	479	C,A	398,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5174	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3964	390.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3139	3139	T	443	T	378	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5174	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3964	390.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2587	2587	A	497	A	421	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	502	folP	852	852	100.0	folP.l15.c4.ctg.1	2012	74.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1321	1323	AGC	100;101;101	A;G;C	87;88;85	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1080	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3762	85.8	1	SNP	p	S91F	0	.	.	271	273	TCC	814	816	TCC	96;96;96	T;C;C	81;84;86	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1080	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3762	85.8	1	SNP	p	D95G	0	.	.	283	285	GAC	826	828	GAC	97;96;97	G;A;C	83;81;83	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1080	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3762	85.8	1	SNP	p	D95N	0	.	.	283	285	GAC	826	828	GAC	97;96;97	G;A;C	83;81;83	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	432	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1812	71.6	0	.	p	.	0	A39T	NONSYN	115	117	GCC	715	717	ACC	129;129;130	A;C;C,A	104;108;104,1	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	432	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1812	71.6	0	.	p	.	0	R44H	NONSYN	130	132	CGC	730	732	CAC	126;127;127	C;A;C	101;101;105	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	432	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1812	71.6	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	913	915	CAC	126;126;126	C;A;C	104;111;112	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	432	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1812	71.6	1	SNP	p	G45D	0	.	.	133	135	GGC	733	735	GGC	127;126;126	G;G;C	106;104;103	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	312	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1468	63.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1036	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3276	94.5	1	SNP	p	D86N	0	.	.	256	258	GAC	752	754	GAC	107;106;106	G;A;C,G	93;84;91,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1036	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3276	94.5	1	SNP	p	S87I	0	.	.	259	261	AGT	755	757	AGT	105;105;105	A,C;G;T	88,1;90;87	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1036	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3276	94.5	1	SNP	p	S87W	0	.	.	259	261	AGT	755	757	AGT	105;105;105	A,C;G;T	88,1;90;87	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1036	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3276	94.5	1	SNP	p	S87R	0	.	.	259	261	AGT	755	757	AGT	105;105;105	A,C;G;T	88,1;90;87	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1036	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3276	94.5	1	SNP	p	S88P	0	.	.	262	264	TCC	758	760	TCC	105;105;106	T,A;C;C,T	88,1;89;91,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1068	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3023	105.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1749	1751	GGC	158;158;157	G;G,T,A;C	128;124,1,1;121	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1450	1452	GCA	130;131;131	G,A;C,A;A	105,1;107,1;109	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1453	1455	ATC	130;130;130	A;T,G;C,A	105;106,1;104,2	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1465	1467	GTG	132;132;134	G;T;G,T	112;111;109,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1465	1467	GTG	132;132;134	G;T;G,T	112;111;109,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1969	1971	ACC	88;89;89	A;C;C	72;75;79	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2023	2025	GCG	90;90;90	G,A;C;G	76,1;69;67	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2023	2025	GCG	90;90;90	G,A;C;G	76,1;69;67	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2146	2148	GGC	81;81;81	G,C;G,T;C	69,1;69,1;69	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2155	2157	GGC	82;82;83	G,C;G;C	72,2;72;73	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	798	penA	1749	1749	100.0	penA.l6.c4.ctg.1	3079	77.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2173	2175	CCG	82;82;82	C;C;G	66;72;66	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1122	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3385	99.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	552	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2460	67.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	1095	1095	C	100	C,T	80,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	545	547	GGA	127;126;124	G;G;A	104;106;104	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	0	.	p	.	0	G50N	NONSYN	148	150	GGC	551	553	AAC	122;122;122	A;A;C,A	107;105;106,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	0	.	p	.	0	F135L	NONSYN	403	405	TTT	806	808	CTT	117;118;118	C;T;T	101;105;101	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	830	832	GGA	114;115;116	G;G;A	101;104;101	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	0	.	p	.	0	D171G	NONSYN	511	513	GAT	914	916	GGT	125;125;126	G,A;G;T	104,1;106;108	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	0	.	p	.	0	G189S	NONSYN	565	567	GGC	968	970	AGC	121;121;121	A;G;C	102;103;101	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1034	1034	T	121	T	98	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	1	SNP	p	G120K	0	.	.	358	360	GGT	761	763	GGT	119;119;119	G;G;T	103;103;98	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	1	SNP	p	A121N	0	.	.	361	363	GCC	764	766	GCC	120;122;122	G;C;C	105;103;102	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	628	porB1b	1035	1035	95.63	porB1b.l15.c30.ctg.1	1659	108.0	1	SNP	p	A121D	0	.	.	361	363	GCC	764	766	GCC	120;122;122	G;C;C	105;103;102	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2066	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5457	113.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2284	2286	AAT	117;117;117	A;A;T	98;97;99	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	310	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1324	69.8	1	SNP	p	V57M	1	.	.	169	171	ATG	616	618	ATG	122;122;122	A;T;G	100;98;98	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
